311 related articles for article (PubMed ID: 2113094)
1. Prospective randomized trial of OKT3- versus horse antithymocyte globulin-based immunosuppressive prophylaxis in heart transplantation.
Costanzo-Nordin MR; O'Sullivan EJ; Johnson MR; Winters GL; Pifarre R; Radvany R; Zucker MJ; Scanlon PJ; Robinson JA
J Heart Transplant; 1990; 9(3 Pt 2):306-15. PubMed ID: 2113094
[TBL] [Abstract][Full Text] [Related]
2. Comparative trial of immunoprophylaxis with RATG versus OKT3.
Griffith BP; Kormos RL; Armitage JM; Dummer JS; Hardesty RL
J Heart Transplant; 1990; 9(3 Pt 2):301-5. PubMed ID: 2113093
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3.
Kirklin JK; Bourge RC; White-Williams C; Naftel DC; Thomas FT; Thomas JM; Phillips MG
J Thorac Cardiovasc Surg; 1990 Apr; 99(4):716-24. PubMed ID: 2108282
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of heart transplant recipients treated with murine antihuman mature T cell monoclonal antibody (OKT3): the Loyola experience.
Costanzo-Nordin MR; O'Sullivan EJ; Hubbell EA; Zucker MJ; Pifarre R; McManus BM; Winters GL; Scanlon PJ; Robinson JA
J Heart Transplant; 1989; 8(4):288-95. PubMed ID: 2504895
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic cytolytic therapy in heart transplantation: monoclonal versus polyclonal antibody therapy.
Laske A; Gallino A; Schneider J; Bauer EP; Carrel T; Pasic M; von Segesser LK; Turina MI
J Heart Lung Transplant; 1992; 11(3 Pt 1):557-63. PubMed ID: 1610864
[TBL] [Abstract][Full Text] [Related]
6. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3.
Renlund DG; O'Connell JB; Gilbert EM; Hammond ME; Burton NA; Jones KW; Karwande SV; Doty DB; Menlove RL; Herrick CM
Transplantation; 1989 Apr; 47(4):599-605. PubMed ID: 2523099
[TBL] [Abstract][Full Text] [Related]
7. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients.
Prieto M; Lake KD; Pritzker MR; Jorgensen CR; Arom KV; Love KR; Emery RW
J Heart Lung Transplant; 1991; 10(6):901-11. PubMed ID: 1661608
[TBL] [Abstract][Full Text] [Related]
8. A prospective randomized controlled trial of initial immunosuppression with ALG versus OKT3 in recipients of cardiac allografts.
Menkis AH; Powell AM; Novick RJ; McKenzie FN; Kostuk WJ; Pflugfelder PW; Brown JE; Rochon J; Chow LH; Stiller C
J Heart Lung Transplant; 1992; 11(3 Pt 1):569-76. PubMed ID: 1610866
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic OKT3 used as induction therapy for heart transplantation.
Starnes VA; Oyer PE; Stinson EB; Dein JR; Shumway NE
Circulation; 1989 Nov; 80(5 Pt 2):III79-83. PubMed ID: 2509108
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD3 monoclonal antibody induction therapy. Immunological equivalency with triple-drug therapy in heart transplantation.
Barr ML; Sanchez JA; Seche LA; Schulman LL; Smith CR; Rose EA
Circulation; 1990 Nov; 82(5 Suppl):IV291-4. PubMed ID: 2121387
[TBL] [Abstract][Full Text] [Related]
11. Unique antithymocyte serum versus OKT3 for induction immunotherapy after heart transplantation.
Frist WH; Merrill WH; Eastburn TE; Atkinson JB; Stewart JR; Hammon JW; Bender JW
J Heart Transplant; 1990; 9(5):489-94. PubMed ID: 2121921
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts.
Soulillou JP; Cantarovich D; Le Mauff B; Giral M; Robillard N; Hourmant M; Hirn M; Jacques Y
N Engl J Med; 1990 Apr; 322(17):1175-82. PubMed ID: 2157982
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal versus polyclonal antibody therapy for prophylaxis against rejection after heart transplantation.
Kormos RL; Herlan DB; Armitage JM; Stein K; Kaufman C; Zeevi A; Duquesnoy R; Hardesty RL; Griffith BP
J Heart Transplant; 1990; 9(1):1-9, discussion 9-10. PubMed ID: 2107288
[TBL] [Abstract][Full Text] [Related]
14. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial.
Kahana L; Narvarte J; Ackermann J; LeFor W; Weinstein S; Wright C; deQuesada A; Baxter J; Shires D
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):5-9. PubMed ID: 2510510
[TBL] [Abstract][Full Text] [Related]
15. Independent risk factors predicting acute graft rejection in cardiac transplant recipients treated by triple drug immunosuppression.
Laufer G; Miholic J; Laczkovics A; Wollenek G; Holzinger C; Hajek-Rosenmeier A; Wuzl G; Schreiner W; Buxbaum P; Wolner E
J Thorac Cardiovasc Surg; 1989 Dec; 98(6):1113-21. PubMed ID: 2586129
[TBL] [Abstract][Full Text] [Related]
16. OKT3 monoclonal antibody given for ten versus fourteen days as immunosuppressive prophylaxis in heart transplantation.
Hegewald MG; O'Connell JB; Renlund DG; Lee HR; Burton NA; Karwande SV; Jones KW; Lassetter JE; Bristow MR
J Heart Transplant; 1989; 8(4):303-9; discussion 309-10. PubMed ID: 2504897
[TBL] [Abstract][Full Text] [Related]
17. Quadruple immunosuppression: comparison of OKT3 and Minnesota antilymphocyte globulin.
Light JA; Khawand N; Aquino A; Ali A; Korb S
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):10-3. PubMed ID: 2510505
[TBL] [Abstract][Full Text] [Related]
18. Ventricular assist devices and aggressive immunosuppression: looking beyond overall survival.
Gonzalez-Stawinski GV; Cook DJ; Chang AS; Banbury MK; Navia JL; Hoercher K; Lober C; Atik FA; Taylor DO; Yamani MH; Young JB; Starling RC; Smedira NG
J Heart Lung Transplant; 2006 Jun; 25(6):613-8. PubMed ID: 16730565
[TBL] [Abstract][Full Text] [Related]
19. A prospective randomized controlled study on the efficacy and tolerance of two antilymphocytic globulins in the prevention of rejection in first-heart transplant recipients.
Schnetzler B; Leger P; Völp A; Dorent R; Pavie A; Gandjbakhch I
Transpl Int; 2002 Jun; 15(6):317-25. PubMed ID: 12072903
[TBL] [Abstract][Full Text] [Related]
20. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation.
Bonaros N; Dunkler D; Kocher A; Imhof M; Grimm M; Zuckermann A; Wolner E; Laufer G
J Heart Lung Transplant; 2006 Sep; 25(9):1154-63. PubMed ID: 16962480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]